Senior Management
Gunilla Osswald
CEO
Born: 1961
Employed since: 2013
Other assignments: Board member of Egetis Therapeutics AB and SpineMedical AB.
Education: Pharmacist; Ph.D. in biopharmacy and pharmacokinetics at Uppsala University, Sweden.
Experience and prior assignments: More than 30 years of experience in drug development. Executive positions at Astra/ AstraZeneca, including Vice President responsible for the product portfolio in neurodegenerative diseases. Board member of SP Process Development AB.
Member of BioArctic’s senior management since: 2013
Total holdings* and warrants in BioArctic: 75,070 Class B shares.
Warrants granting acquisition rights to 150,000 Class B shares (2019/2028 program).
Gunilla Andersson
Vice President HR
Born: 1961
Employed since: 2019 (contracted since 2014)
Other assignments: Manages her own consulting company focusing on HR.
Education: B.Sc. Human Resource Development and Labor Relations with a specialization in labor rights from Lund University, Sweden.
Experience and prior assignments: 30 years of experience as HR consultant and HR manager in educational organizations and pharma companies such as Pharmacia and Novartis.
Member of BioArctic’s senior management since: 2019
Total holdings* and warrants in BioArctic: 0 shares.
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)
Oskar Bosson
Vice President Investor Relations & Communications
Born: 1976
Employed since: 2020
Other assignments: –
Education: M.Sc. Molecular Biotechnology and B.A. in Business Administration from Uppsala University
Experience and prior assignments: 17 years of experience from the communication field globally. Held senior positions in companies such as Sobi, Ovako and most recently Elekta.
Member of BioArctic’s senior management since: 2020
Total holdings* and warrants in BioArctic: 3,793 Class B shares.
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)
Johanna Fälting
Vice President Head of Research
Born: 1972
Employed since: 2012
Other assignments: –
Education: Ph.D. in Physiology, Stockholm University; Licentiate degree in physiology, Stockholm University; Master’s degree in biology, Stock-holm University, Sweden.
Experience and prior assignments: 19 years of experience in neuroscience/ pharmacology, drug research, translational science and development in the global pharma and biotech industry.
Member of BioArctic’s senior management since: 2012
Total holdings* and warrants in BioArctic: 38,355 Class B shares.
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)
Anna-Kaija Grönblad
Chief Commercial Officer
Born: 1968
Employed since: 2021 (contracted since 2020)
Other assignments: –
Education: B.A. in Business Administration from Uppsala University, Sweden.
Experience and prior assignments: 25 years of experience from the pharmaceutical industry and private healthcare. Over the years, she has worked in various commercial roles in Sweden and the Nordic and Baltic countries, and in a number of therapy areas with a focus on market access, launch preparations and organizational development. She most recently came from the role as CEO of Sanofi AB, where she was also General Manager Nordic & Baltic countries for General Medicine.
Member of BioArctic’s senior management since: 2021
Total holdings* and warrants in BioArctic: 9,300 Class B shares, privately and through Saimi AB. Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)
Lars Lannfelt
Senior Vice President University Collaborations. Founder of BioArctic in 2003.
Born: 1949
Employed since: 2016
Other assignments: Board member of Demban AB and LPB Sweden AB.
Education: Medical degree (specialist in psychiatry) and doctoral thesis at Karolinska Institutet, Stockholm, Sweden; Associate Professor of Neurogenetics at Karolinska Institutet, specialist in geriatrics.
Experience and prior assignments: More than 35 years of experience in research into Alzheimer’s disease and other neurodegenerative diseases. Professor of Geriatrics at Uppsala University; Senior Professor at Uppsala University and member of the Royal Swedish Academy of Sciences. Founder of BioArctic in 2003, Chairman of the Board and a number of assignments and roles in the company.
Member of BioArctic’s senior management since: 2003
Total holdings* and warrants in BioArctic:
8,639,998 Class A shares through Demban AB.
20,885,052 Class B shares through Demban AB.
0 warrants
Jan Mattsson
Vice President Finance, CFO
Born: 1960
Employed at the company since: 2017.
Other assignments – Experience and prior assignments: More than 30 years of experience in business and administration, including CFO at Sefina Finance AB, Allenex AB, Argnor Wireless Ventures AB, Logitall AB and Investment AB Kinnevik.
Education: MBA from Örebro University.
Member of BioArctic’s senior management since: 2017
Total holdings* and warrants in BioArctic: 36,270 Class B shares, privately and through Almsäter Interim Management AB.
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program
Mikael Moge
Vice President Chemistry, Manufacturing & Control
Born: 1967
Employed since: 2012
Other assignments – Experience and prior assignments: 23 years of experience in drug development and 19 years of experience as R&D director in process development and GMP manufacturing. Former section manager in Process R&D at AstraZeneca.
Education: Master of Engineering chemical engineering, KTH Royal Institute of Technology; Ph.D. in organic chemistry, KTH; Stockholm, Sweden.
Member of BioArctic’s senior management since: 2012
Total holdings* and warrants in BioArctic: 9,360 Class B shares.
Warrants granting acquisition rights to 19,000 Class B shares (2019/2028 program)
Christer Möller
Vice President Pre-Clinical Development, Chief Scientific Officer
Born: 1959
Employed at the company since: 2006.
Other assignments – Experience and prior assignments: 21 years of experience in developing protein drugs from idea to clinical trials including leading positions at small biotech/pharma companies such as Zymenex A/S. In addition, comprehensive academic experience in pursuing research projects concerning growth factors and preclinical research in diabetes.
Education: B.Sc. in Biology, Stockholm University, Sweden; Ph.D. in Medical Science, Karolinska Institutet, Stockholm, Sweden.
Member of BioArctic’s senior management since: 2006
Total holdings* and warrants in BioArctic: 52,770 Class B shares.
Warrants granting acquisition rights to 21,000 Class B shares (2019/2028 program)
Tomas Odergren
Chief Medical Officer
Born: 1959
Employed since: 2019 (contracted since 2016)
Other assignment: Senior Clinical Consultant at GKeller Consulting
Education: MD Uppsala University, PhD Karolinska Institute, Neurologist certified by the Swedish Medical Society, Diploma in Pharmaceutical Medicine EUCOR/ECPM.
Experience and prior assignments: More than 20 years’ experience from the pharmaceutical industry in leading positions in clinical development at AstraZeneca and H Lundbeck. Chief Specialist ICR Neurology H Lundbeck A/S (2015-2017)
Member of BioArctic’s senior management since: 2020
Total holdings* and warrants in BioArctic: 5,700 Class B-shares.
Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program)
*Includes holdings by self, closely associated persons, controlled companies or otherwise controlled.